Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Rheumatol. 2022 Apr 1;49(9):1058–1066. doi: 10.3899/jrheum.211084

Table 2:

Uncertainty and Mental Health (Overall and Stratified by Disease)

Overall AAV IgG4-RD SSc P-Value
N 132 41 61 30
MUIS n (%)
 Median, IQR 55.0 [48.0, 62.0] 55.0 [48.0, 62.0] 53.0 [48.0, 58.0] 59.0 [55.0, 66.0] 0.002
 Q1 (22–44) 21 (15.9) 8 (19.5) 12 (19.7) 1 (3.3)
 Q2 (44–66) 97 (73.5) 25 (61.0) 48 (78.7) 24 (80.0)
 Q3 (66–88) 13 (9.8) 7 (17.1) 1 (1.6) 5 (16.7)
 Q4 (88–110) 1 (0.8) 1 (2.4) 0 (0.0) 0 (0.0)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PHQ-8 n (%)
 Median, IQR 3.0 [1.0, 6.0] 4.0 [2.0, 9.0] 2.5 [0.5, 5.0] 3.0 [1.0, 7.0] 0.03
 Minimal (0–4) 84 (63.6) 21 (51.2) 44 (72.1) 19 (63.3) 0.10*
 Mild (5–9) 31 (23.5) 10 (24.4) 13 (21.3) 8 (26.7)
 Moderate (10–14) 5 (3.8) 4 (9.8) 0 (0.0) 1 (3.4)
 Moderately Severe (15–19) 5 (3.8) 2 (4.9) 2 (3.3) 1 (3.4)
 Severe (20–24) 5 (3.8) 4 (9.8) 1 (1.6) 0 (0.0)
 Missing 2 (1.5) 0 (0.0) 1 (1.6) 1 (3.4)
GAD-7 n (%)
 Median, IQR 2.0 [0.0, 5.5] 5.0 [2.0, 8.0] 1.0 [0.0, 4.0] 2.0 [0.0, 5.0] 0.002
 Minimal (0–4) 90 (68.2) 20 (48.8) 48 (78.7) 22 (73.3) 0.005*
 Mild (5–9) 34 (25.8) 16 (39.0) 11 (18.0) 7 (23.3)
 Moderate (10–14) 6 (4.5) 4 (9.8) 1 (1.6) 1 (3.3)
 Severe (15–21) 2 (1.5) 1 (2.4) 1 (1.6) 0 (0.0)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SIP n (%)
 Median, IQR 1.0 [0.0, 6.0] 2.0 [0.0, 6.0] 1.0 [0.0, 7.0] 1.0 [0.0, 5.0] 0.60
 Q1 (0–5) 92 (69.7) 27 (65.9) 41 (67.2) 24 (80.0)
 Q2 (6–11) 34 (25.8) 12 (29.3) 16 (26.2) 6 (20.0)
 Q3 (12–16) 6 (4.5) 2 (4.9) 4 (6.6) 0 (0.0)
 Q4 (17–22) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Missing 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)

AAV: ANCA-Associated Vasculitis; IgG4-RD: IgG4-Related Disease; SSc: Systemic Sclerosis; MUIS: Mishel Uncertainty in Illness Scale; PHQ-8: Patient Health Questionnaire depression scale; GAD-7: General Anxiety Disorder; SIP: Sickness Impact Profile

*

P-value compares the proportion of patients with at least mild depression or anxiety across the three disease groups.